Race Is Associated with Bortezomib but Not Lenalidomide Utilization during First-Line Treatment of Multiple Myeloma
نویسندگان
چکیده
منابع مشابه
Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma
BACKGROUND Simultaneous multiple myeloma (MM) and pulmonary adenocarcinoma is a rare occurrence, and thus, treatment is a challenge. This study reports on 1 such case of MM with concurrent lung cancer, where an accurate diagnosis was made and the patient underwent treatment for both cancers. CASE SUMMARY A 68-year-old man presented with 2 months of progressive lower back pain. Visualization w...
متن کاملEfficacy of Bortezomib as First-Line Treatment for Patients with Multiple Myeloma
Recent years have seen a dramatic change in the approach towards diagnosing and treating Multiple Myeloma. Newer and more target specific approach to treatment has prolonged the survival for patients with multiple myeloma. The proteasome inhibitors make an important class of anti-myeloma drugs that disrupts the proteolytic machinery of the tumor cells preferentially, enhancing their susceptibil...
متن کاملTreatment of Multiple Myeloma
Les traitements classiques de myelome multiple et les schemas differents proposes ont ete mis en revue. La poly chimiotherapie de la maladie avec une com-binaison de cyclophosphamide, B.C.N.U. Alkeran, Perdnisone et Vincristine a donnee une meilleur Resultat ceci surtout dans les formes graves et rapidement progressive de la maladie. D'autres sehemas therapeutiques sont en cours.
متن کاملBortezomib for the treatment of multiple myeloma.
Bortezomib is the first proteasome inhibitor drug tested in human patients. Bortezomib demonstrates a particular clinical utility in the treatment of multiple myeloma (MM), where it is the only one of the new drugs administered as mono-therapy that prolongs survival. The significant problem for the consistent pursuit of bortezomib was neurotoxicity, which has been significantly reduced by regis...
متن کاملCD93 is Selectively Expressed on Human Myeloma Cells but Not on B Lymphocytes
Background: CD93 has originally been known as a C1q receptor, and many studies have demonstrated that CD93 is expressed on hematopoietic stem cells, B cell progenitors, myeloid and monocytic cells. Moreover, CD93 is shown to be expressed on long-lived plasma cells, and CD93 deficient-mice display an impairment in plasma cell development. Objective: To investiga...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2017
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood.v130.suppl_1.862.862